# VALIDATION OF BIOANALYTICAL ASSAYS AND IND- ENABLING GLP PD/PK TOXICOLOGY STUDIES

> **NIH NIH N01** · BATTELLE CENTERS/PUB HLTH RES & EVALUATN · 2024 · $1,553,595

## Abstract

The URGenT Network Services indefinite delivery, indefinite quantity (IDIQ) contract provides neuroscience product developers/innovators with a full range of industry-style, biologic and drug development services and expertise for their development of therapeutics for neurological diseases.  These product developers/researchers are funded through other programs at the National Institutes of Health (NIH) but may lack the entire suite of capabilities necessary to advance their candidate product 
to a phase I clinical trial. Therefore, the IDIQ contract augments the progress of the candidate product by providing the support required at the specific stage of its development and optimization path. The services offered through this contract are bioanalytical assay services and GLP dose-escalation for investigational new drug (IND)-enabling toxicological studies, and support through phase I 
clinical trial.

## Key facts

- **NIH application ID:** 11212584
- **Project number:** 75N95022D00021-0-759502400001-1
- **Recipient organization:** BATTELLE CENTERS/PUB HLTH RES & EVALUATN
- **Principal Investigator:** JAMES GRIDLEY
- **Activity code:** N01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $1,553,595
- **Award type:** —
- **Project period:** 2024-03-11 → 2027-03-10

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/11212584

## Citation

> US National Institutes of Health, RePORTER application 11212584, VALIDATION OF BIOANALYTICAL ASSAYS AND IND- ENABLING GLP PD/PK TOXICOLOGY STUDIES (75N95022D00021-0-759502400001-1). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/11212584. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*